Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Accustem Sciences Inc.

Get SEC filing alerts via email and in your feed for Accustem Sciences Inc.

ACUT

Accustem Sciences Inc.

About Accustem Sciences Inc.

AccuStem Sciences, Inc. is a clinical-stage diagnostics company developing proprietary genomic tests to improve cancer patient outcomes. Its key products include the MSC test for lung nodule malignancy risk and StemPrintER, a multi-gene assay predicting breast cancer recurrence risk. Targeting oncology care providers and patients, AccuStem leverages validated molecular diagnostics to support personalized treatment decisions, focusing initially on the U.S. market with plans for broader tumor applications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Accustem Sciences Inc.

1
1
Accustem Sciences Inc. AccuStem Sciences Reports Increased Net Loss and Rising Operating Expenses for Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Accustem Sciences Inc. AccuStem Sciences Reports Increased Net Loss and Seeks Funding for Product Development

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Accustem Sciences Inc. AccuStem Sciences Reports Q3 2025 Financial Results with Increased Losses and Strategic Developments

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Accustem Sciences Inc. AccuStem Sciences Reports Increased Losses and Significant Asset Growth in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Accustem Sciences Inc. AccuStem Sciences Reports Q1 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Accustem Sciences Inc. AccuStem Sciences Reports $1.5 Million Net Loss for Fiscal Year 2024, Focuses on Product Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Accustem Sciences Inc. AccuStem Sciences Reports Improved Financial Results, Continues to Pursue Additional Funding

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Accustem Sciences Inc. AccuStem Sciences Reports Reduced Net Loss, Improved Cash Position, and Pursues Additional Equity Financing

Via official filing (AI summary) | over 1 year ago | 0 comments